Nuformix Posts 2025 Annual Report and Sets Date for 2026 AGM

The latest update is out from Nuformix Plc ( (GB:NFX) ).

Nuformix plc has published its Annual Financial Report for the year ended 30 September 2025 and issued the notice for its 2026 Annual General Meeting, which will take place in London on 3 March 2026. The availability of the report and AGM documentation via the company’s website provides shareholders with updated financial and strategic information and marks a routine but important step in its corporate governance calendar as it continues to advance its preclinical pipeline in fibrosis and oncology.

The most recent analyst rating on (GB:NFX) stock is a Hold with a £0.19 price target. To see the full list of analyst forecasts on Nuformix Plc stock, see the GB:NFX Stock Forecast page.

Spark’s Take on GB:NFX Stock

According to Spark, TipRanks’ AI Analyst, GB:NFX is a Neutral.

The score is held down primarily by weak financial performance—zero recent revenue, ongoing losses, and persistent negative free cash flow—despite the benefit of no debt. Technicals add downside risk with price below key short/medium-term averages and negative MACD, while valuation is also constrained by a negative P/E and no dividend support.

To see Spark’s full report on GB:NFX stock, click here.

More about Nuformix Plc

Nuformix plc is a UK-listed pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology through drug repurposing. Leveraging its expertise in discovering, developing and patenting novel drug forms with improved physical properties, the company aims to create differentiated products, including new dosages and delivery routes, and maintains a pipeline of preclinical assets positioned for early licensing opportunities.

Average Trading Volume: 28,799,431

Technical Sentiment Signal: Sell

Current Market Cap: £4.64M

See more data about NFX stock on TipRanks’ Stock Analysis page.